396 related articles for article (PubMed ID: 24847116)
21. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
23. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
24. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
[TBL] [Abstract][Full Text] [Related]
25. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
26. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
27. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
28. MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
Srivastava SK; Khan MA; Anand S; Zubair H; Deshmukh SK; Patel GK; Singh S; Andrews J; Wang B; Carter JE; Singh AP
Br J Cancer; 2022 May; 126(8):1205-1214. PubMed ID: 34837075
[TBL] [Abstract][Full Text] [Related]
29. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
31. USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response.
Li Y; Luo K; Yin Y; Wu C; Deng M; Li L; Chen Y; Nowsheen S; Lou Z; Yuan J
Nat Commun; 2017 Jun; 8():15752. PubMed ID: 28569838
[TBL] [Abstract][Full Text] [Related]
32. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
[TBL] [Abstract][Full Text] [Related]
33. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
35. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
36. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
[TBL] [Abstract][Full Text] [Related]
38. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
40. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
